JAZZN Stock Chart & Stats
$2985.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$2,059.00 - $3,120.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$275.42B
Enterprise Value$15.04K
Total Cash (Recent Filing)$2.87B
Total Debt (Recent Filing)$5.42B
Price to Earnings (P/E)621.6
Beta-0.54
Next Earnings
Aug 03, 2026EPS Estimate
108.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.41
Shares Outstanding62,817,627
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.40
Price to Sales (P/S)2.43
P/FCF Ratio9.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4,631.09Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Generation And FCFSustained high operating cash flow and robust free cash flow provide durable financial flexibility to fund R&D, support launches, service debt, and pursue M&A or partnerships. This cash generation underpins multi-quarter strategic investment even if reported earnings swing.
Diversified Commercial PortfolioMultiple growing franchises across oncology, sleep, and epilepsy reduce single-product concentration risk and enable sustained revenue growth. Early uptake of new launches like Midevo plus established specialty drugs supports recurring sales and cross-product commercial leverage.
Pipeline Momentum And Regulatory CatalystsPriority review and imminent PDUFA for zanidatumab plus multiple registrational readouts create structural upside to the commercial runway. Successful approvals and positive OS data can materially expand indications, diversify revenue, and improve long-term growth prospects.
Bears Say
Earnings Volatility And Weak Net MarginSharp swings in reported profitability despite high gross margins signal earnings-quality risk; this reduces predictability of reported results, complicates planning, and can pressure credit metrics if adverse events recur, limiting strategic optionality over quarters.
High Absolute Debt LoadAlthough leverage metrics have improved, a sizeable absolute debt burden increases interest and refinancing risk, particularly given profit volatility. Elevated debt can constrain capital allocation, limit M&A flexibility, and raise sensitivity to policy or reimbursement shifts.
Competitive And IP/legal Risks In Core MarketsStructural threats from generics, potential new wake-promoters, and active ANDA litigation create durable downside to sales and margins in sleep and oncology franchises. These factors can erode pricing power, accelerate revenue declines, and prolong uncertainty around market access.
Jazz Pharmaceuticals News
JAZZN FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $2059.00 and its highest was $3120.00 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $275.42B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Aug 03, 2026 which is in 10 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on May 05, 2026. The company reported $111.006 earnings per share for the quarter, beating the consensus estimate of $81.259 by $29.748.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 108.12.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 62,817,627 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $111.006 in its last earnings report, beating expectations of $81.259. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in MX:JAZZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jazz Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4,631.09 (― Downside)
$4,631.09 (― Downside)
Blogger Sentiment
Bullish
MX:JAZZN Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth $48.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.82%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZN Stock 12 Month Forecast
Average Price Target
$4,631.09